ESR1 and neoplasm: Regarding tumor mutation burden (TMB), both claudin-low groups had very low numbers of cases with a TMB above 10 mutations/Mb, while the basal ER-negative/HER2-negative group had a high TMB in 14% of cases (Table 3).